StrideBio

company

About

StrideBio is a gene therapy company that develops genetic medicines with curative potential for patients with devastating conditions.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$15.70M
Industries
Biotechnology,Health Care,Information Technology,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active

StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies.

The company was founded in 2015 and is headquartered in Durham, North Carolina.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$15.70M
StrideBio has raised a total of $15.70M in funding over 2 rounds. Their latest funding was raised on Jun 13, 2018 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 13, 2018 Series A $15.70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
StrideBio is funded by 1 investors. UCB are the most recent investors.
Investor Name Lead Investor Funding Round
UCB Series A